|
|
Volumn 13, Issue 8, 2014, Pages 563-565
|
|
MET inhibitors start on road to recovery
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ABT 700;
ALTIRATINIB;
AMG 337;
ANAPLASTIC LYMPHOMA KINASE;
ANTINEOPLASTIC AGENT;
ARQULE;
BIOLOGICAL MARKER;
CABOZANTINIB;
CRIZOTINIB;
ERLOTINIB;
FICLATUZUMAB;
FORETINIB;
HMPL 504;
INC 280;
LY 2801653;
LY 2875358;
METMAB;
MGCD 265;
MSC 2156119J;
ONARTUZUMAB;
RILOTUMUMAB;
SAR 125844;
SCATTER FACTOR;
TIVANTINIB;
UNCLASSIFIED DRUG;
VOLITINIB;
ANGIOGENESIS;
AUTOCRINE EFFECT;
AUTOPHOSPHORYLATION;
CELL INVASION;
CELL PROLIFERATION;
CELL SURVIVAL;
CHROMOSOME 7;
COST EFFECTIVENESS ANALYSIS;
DIMERIZATION;
EX VIVO STUDY;
FLUORESCENCE IN SITU HYBRIDIZATION;
GENE;
GENE AMPLIFICATION;
GENE MUTATION;
GENE TRANSLOCATION;
HUMAN;
IMMUNOHISTOCHEMISTRY;
LIVER CANCER;
LUNG CANCER;
MET GENE;
NOTE;
PARACRINE SIGNALING;
PATIENT SELECTION;
PHASE 1 CLINICAL TRIAL (TOPIC);
PHASE 2 CLINICAL TRIAL (TOPIC);
PHASE 3 CLINICAL TRIAL (TOPIC);
PRIORITY JOURNAL;
SIGNAL TRANSDUCTION;
SOLID TUMOR;
STOMACH CANCER;
TREATMENT FAILURE;
TUMOR GROWTH;
ANTINEOPLASTIC AGENTS;
DRUG DISCOVERY;
HUMANS;
LUNG NEOPLASMS;
PROTO-ONCOGENE PROTEINS C-MET;
|
|
EID: 84905373271
PISSN: 14741776
EISSN: 14741784
Source Type: Journal
DOI: 10.1038/nrd4406 Document Type: Note |
|
Times cited : (44)
|
|
References (0)
|
